3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Non-Muscle Invasive Bladder Neoplasms
6
Urinary Bladder Neoplasms
5
Testicular Neoplasms
3
Prostatic Neoplasms
2
Wilms Tumor
1
Upper Tract Urothelial Carcinoma
1
Testicular Germ Cell Tumor
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Disease Progression
1
Interventions
Cyclophosphamide
4
Etoposide
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Sirolimus
2
Paclitaxel
2
Mesna
2
Melphalan
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
Busulfan
2
Brentuximab Vedotin
2
tremelimumab
1
ripretinib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
guadecitabine
1
fosaprepitant
1
fludarabine phosphate
1
durvalumab
1
bintrafusp alfa protein, human
1
avelumab
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Epirubicin
×
Genitourinary
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled